Rationale for and use of NMDA receptor antagonists in Parkinson's disease

Pharmacology and Therapeutics

Volumn 102, Issue 2, 2004, Pages 155-174

  Hallett, Penelope J ^a   Standaert, David G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid; calcium calmodulin dependent protein kinase II; AMPA; Basal ganglia; CaMKII; DARPP 32; Glutamate; Levodopa; NMDA receptors; Parkinson's disease; Striatum

Indexed keywords

AMANTADINE; AMINO ACID RECEPTOR; ANTIPARKINSON AGENT; CI 1041; CO 101244; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IFENPRODIL; ION CHANNEL; LEVODOPA; LIGAND; MDL 100453; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PRAMIPEXOLE; PROTEIN SUBUNIT; RECEPTOR SUBUNIT; ROPINIROLE; TRAXOPRODIL; UNCLASSIFIED DRUG;

AGONIST; BASAL GANGLION; BINDING SITE; BRAIN NERVE CELL; BRAIN REGION; CELL DAMAGE; CHANNEL GATING; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG UTILIZATION; DYSKINESIA; EFFERENT NERVE; EXPERIMENTAL MODEL; GENE EXPRESSION; GENETIC ANALYSIS; GLOBUS PALLIDUS; HUMAN; INTERNEURON; NERVE CELL PLASTICITY; NERVE PROJECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; HUMANS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 2542431131     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.04.001     Document Type: Review

References (258)

1. Agid Y., Chase T., Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet. 351:1998;851-852
2. Albers D.S., Weiss S.W., Iadorola M.J., Standaert D.G. Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience. 89:1999;209-220
3. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738
4. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375
5. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.S., Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48
6. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 12:1990;366-371
7. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits-parallel substrates for motor oculomotor "prefrontal" and "limbic" functions. Feenstra M.G.P. Prefrontal Cortex. Its Structure, Function, and Pathology. 1990;119-146 Elsevier, Amsterdam
8. Aosaki T., Tsubokawa H., Ishida A., Watanabe K., Graybiel A.M., Kimura M. Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorimotor conditioning. J Neurosci. 14:1994;3969-3984
9. Arbuthnott G.W., Ingham C.A., Wickens J.R. Dopamine and synaptic plasticity in the neostriatum. J Anat. 196:2000;587-596
10. Benabid A.L. Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol. 13:2003;696-706
11. Bergman H., Wichmann T., DeLong M. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:1990;1436-1438
12. Betarbet R., Sherer T.B., Di Monte D.A., Greenamyre J.T. Mechanistic approaches to Parkinson's disease. Brain Pathol. 12:2002;499-510
13. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 21:2001;6853-6861
14. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev. 21:1997;447-453
15. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther. 290:1999;1034-1040
16. Blandini F., Greenamyre J.T., Fancellu R., Nappi G. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurol Sci. 22:2001;49-50
17. Blank T., Nijholt I., Kügler H., Bersing H., Fienberg A., Greengard P., Speiss J. The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses. Proc Natl Acad Sci USA. 94:1997;14859-14864
18. Brakeman P.R., Lanahan A.A., O'Brien R., Roche K., Barnes C.A., Huganir R.L., Worley P.F. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature. 386:1997;284-288
19. Bredt D.S., Nicoll R.A. AMPA receptor trafficking at excitatory synapses. Neuron. 40:2003;361-379
20. Brouillet E., Beal M.F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport. 4:1993;387-390
21. Buchholzer M.L., Klein J. NMDA-induced acetylcholine release in mouse striatum: role of NO synthase isoforms. J Neurochem. 82:2002;1558-1560
22. Buller A.L., Monaghan D.T. Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes. Eur J Pharmacol. 320:1997;87-94
23. Bustos G., Abarca J., Forray M.I., Gysling K., Bradberry C.W., Roth R.H. Regulation of excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies. Brain Res. 585:1992;105-115
24. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci. 4:1992;929-935
25. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116(Pt. 2):1993;433-452
26. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19:1996;19-24
27. Calabresi P., Centonze D., Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23:2000;S57-S63
28. Calabresi P., Giacomini P., Centonze D., Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol. 47:2000;S60-S68
29. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23:2000;120-126
30. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog Neurobiol. 61:2000;231-265
31. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., Di P.T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry. 26:2002;127-138
32. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis. 14:2003;404-416
33. Carroll C.B., Holloway V., Brotchie J.M., Mitchell I.J. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berl). 119:1995;55-65
34. Carvalho G.A., Nikkhah G. Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol. 171:2001;405-417
35. Cattabeni F., Gardoni F., Di Luca M. Pathophysiological implications of the structural organization of the excitatory synapse. Eur J Pharmacol. 375:1999;339-347
36. Centonze D., Grande C., Saulle E., Martin A.B., Gubellini P., Pavon N., Pisani A., Bernardi G., Moratalla R., Calabresi P. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci. 23:2003;8506-8512
37. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA. 90:1993;9576-9580
38. Cepeda C., Colwell C.S., Itri J.N., Chandler S.H., Levine M.S. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol. 79:1998;82-94
39. Cepeda C., Itri J.N., Flores-Hernandez J., Hurst R.S., Calvert C.R., Levine M.S. Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur J Neurosci. 14:2001;1577-1589
40. Chase T.N. Levodopa therapy: consequences of nonphysiologic replacement of dopamine. Neurology. 50(Suppl. 5):1998;S17-S25
41. Chen L., Huang L.Y. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature. 356:1992;521-523
42. Chen C., Leonard J.P. Protein tyrosine kinase-mediated potentiation of currents from cloned NMDA receptors. J Neurochem. 67:1996;194-200
43. Chenard B.L., Menniti F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des. 5:1999;381-404
44. Chergui K., Charléty J., Akaoka H., Saunier C.F., Brunet J.-L., Buda M., Scensson T.H., Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci. 5:1993;137-144
45. Chesler M., Kaila K. Modulation of pH by neuronal activity. Trends Neurosci. 15:1992;396-402
46. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 13:1990;171-182
47. Christie J.M., Jane D.E., Monaghan D.T. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp Ther. 292:2000;1169-1174
48. Christoffersen C.L., Meltzer L.T. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons - possible preferential role for N-methyl-D-aspartate receptors. Neuroscience. 67:1995;373-381
49. Colbran R.J. Targeting of calcium/calmodulin-dependent protein kinase II. Biochem J. 378:2004;1-16
50. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 37:1997;205-237
51. Counihan T.J., Landwehrmeyer G.B., Standaert D.G., Kosinski C.M., Scherzer C.R., Daggett L.P., Velicelebi G., Young A.B., Penney J.B. Expression of N-methyl-D-aspartate receptor subunit mRNA in human mesencephalic dopamine neurons. J Comp Neurol. 390:1998;91-101
52. Craven S.E., Bredt D.S. PDZ proteins organize synaptic signalling pathways. Cell. 93:1998;495-498
53. Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. (2):2003;. CD003467
54. Crossman A.R., Peggs D., Boyce S., Luquin M.R., Sambrook M.A. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology. 28:1989;1271-1273
55. Cui Z., Wang H., Tan Y., Zaia K.A., Zhang S., Tsien J.Z. Inducible and reversible NR1 knockout reveals crucial role of the NMDA receptor in preserving remote memories in the brain. Neuron. 41:2004;781-793
56. Damsma G., Robertson G.S., Tham C.S., Fibiger H.C. Dopaminergic regulation of striatal acetylcholine release: importance of D1 and N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 259:1991;1064-1072
57. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., Chase T.N., Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 16:2001;515-520
58. Desce J.M., Godeheu G., Galli T., Glowinski J., Cheramy A. Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes. Brain Res. 640:1994;205-214
59. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum-ACh/dopamine/NMDA interactions. Trends Neurosci. 17:1994;228-233
60. DiFiglia M., Pasik T., Pasik P. Ultrastructure of golgi-impregnated and gold-toned spiny and aspiny neurons in the monkey neostriatum. J Neurocytol. 9:1980;471-492
61. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev. 51:1999;7-61
62. Dunah A.W., Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci. 21:2001;5546-5558
63. Dunah A.W., Standaert D.G. Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. J Neurochem. 85:2003;935-943
64. Dunah A.W., Wang Y.H., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition and phosphorylation of striatal NMDA glutamate receptors in the rat 6-OHDA models of Parkinson's disease. Mol Pharmacol. 57:2000;342-352
65. Dunah A.W., Sirianni A.C., Fienberg A.A., Bastia E., Schwarzschild M.A., Standaert D.G. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol. 65:2004;121-129
66. Duvoisin R.C. Role of genetics in the cause of Parkinson's disease. Mov Disord. 13(Suppl. 1):1998;7-12
67. Elbaz A., Bower J.H., Peterson B.J., Maraganore D.M., McDonnell S.K., Ahlskog J.E., Schaid D.J., Rocca W.A. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 60:2003;91-96
68. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588
69. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs. later L-DOPA. Arch Neurol. 56:1999;529-535
70. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 281:1998;838-842
71. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C.R., Jokel E.S., Fienberg A.A., Greengard P., Levine M.S. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol. 88:2002;3010-3020
72. Galli T., Desce J.M., Artaud F., Kemel M.L., Cheramy A., Glowinski J. Modulation of GABA release by α-amino-3-hydroxy-5-methylisoxazole-4- propionate and N-methyl-D-aspartate receptors in matrix-enriched areas of the rat striatum. Neuroscience. 50:1992;769-780
73. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia- thalamocortical circuits in Parkinson syndrome. Brain Res. 741:1996;142-152
74. Gibb W.R. Neuropathology of Parkinson's disease and related syndromes. Neurol Clin. 10:1992;361-376
75. Götz T., Kraushner U., Geiger J., Lübke J., Berger T., Jonas P. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. J Neurosci. 17:1997;204-215
76. Gracy K.N., Pickel V.M. Ultrastructural immunocytochemical localization of the N-methyl-D-aspartate receptor and tyrosine hydroxylase in the shell of the rat nucleus accumbens. Brain Res. 739:1996;169-181
77. Gracy K.N., Svingos A.L., Pickel V.M. Dual ultrastructural localization of μ-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens. J Neurosci. 17:1997;4839-4848
78. Graham W.C., Robertson R.G., Sambrook M.A., Crossman A.R. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci. 47:1990;PL91-PL97
79. Graybiel A.M. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem. 70:1998;119-136
80. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 35:1994;655-661
81. Greengard P., Allen P.B., Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 23:1999;435-447
82. Grosshans D.R., Clayton D.A., Coultrap S.J., Browning M.D. LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1. Nat Neurosci. 5:2002;27-33
83. Haber S.N. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat. 26:2003;317-330
84. Hadj Tahar A., Gregoire L., Darre A., Belanger N., Meltzer L., Bedard P.J. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis. 15:2004;171-176
85. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Striatal NMDA receptor subunit abundance and phosphorylation in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. 2003 Abstract Viewer/Itinerary Planner. 2003;Society for Neuroscience, Washington, DC. Online. Program No. 946.7
86. Halpain S., Girault J.A., Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 343:1990;369-372
87. Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., Lozano A.M. The subthalamic nucleus in the context of movement disorders. Brain. 127:2004;4-20
88. Hersch S.M., Ciliax B.J., Gutekunst C.-A., Rees H.D., Heilman C.J., Yung K.K.L., Bolam J.P., Ince E., Yi H., Levey A.I. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci. 15:1995;5222-5237
89. Hess S.D., Daggett L.P., Deal C., Lu C.C., Johnson E.C., Veliçelebi G. Functional characterization of human N-methyl-D-aspartate subtype 1A/2D receptors. J Neurochem. 70:1998;1269-1279
90. Holemans S., Javoy F., Agid Y., Laterre E.C., Maloteaux J.M. [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy. Brain Res. 565:1991;154-157
91. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 17:1994;31-108
92. Holt D.J., Graybiel A.M., Saper C.B. Neurochemical architecture of the human striatum. J Comp Neurol. 384:1997;1-25
93. Honer M., Benke D., Laube B., Kuhse J., Heckendorn R., Allgeier H., Angst C., Monyer H., Seeburg P.H., Betz H., Mohler H. Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. J Biol Chem. 273:1998;11158-11163
94. Hoogenraad C.C., Sheng M. The return of the exocyst. Nat Cell Biol. 5:2003;493-495
95. Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H., Yokoi M., Akazawa C., Shigemoto R., Mizuno N., Masu M., Nakanishi S. Molecular characterization of the family of N-methyl-D-aspartate receptor subunits. J Biol Chem. 268:1993;2836-2843
96. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord. 13:1998;24-34
97. Johnson S.W., Seutin V., North R.A. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of the electrogenic sodium pump. Science. 258:1992;665-667
98. Kato A., Ozawa F., Saitoh Y., Fukazawa Y., Sugiyama H., Inokuchi K. Novel members of the Vesl/homer family of PDZ proteins that bind metabotropic glutamate receptors. J Biol Chem. 273:1998;23969-23975
99. Kaur S., Starr M.S. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat. Neuroscience. 76:1997;345-354
100. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurons: chemical, physiological, and morphological characterization. Trends Neurosci. 18:1995;527-535
101. Kennedy M.B. Signal transduction molecules at the glutamatergic postsynaptic membrane. Brain Res Rev. 26:1998;243-257
102. Kim E., Cho K.-O., Rothschild A., Sheng M. Heteromultimerization and NMDA receptor-clustering activity of chapsyn-110, a member of the PSD-95 family of proteins. Neuron. 17:1996;103-113
103. Kim E., Naisbitt S., Hsueh Y.-P., Rao A., Rothschild A., Craig A.M., Sheng M. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol. 136:1997;669-678
104. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 329:1998;605-608
105. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol. 28:1990;539-546
106. Klockgether T., Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol. 34:1993;585-593
107. Kohr G., Seeburg P.H. Subtype-specific regulation of recombinant NMDA receptor-channels by protein tyrosine kinases of the src family. J Physiol. 492(Pt. 2):1996;445-452
108. Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 269:1995;1737-1740
109. Krebs M.-O., Trovero F., Desban M., Gauchy C., Glowinsky J., Kemel M.-L. Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome- and matrix-enriched areas of the rat striatum. J Neurosci. 11:1991;1256-1262
110. 2+ blockade in NMDA receptor channels. J Neurosci. 16:1996;3549-3558
111. Küppenbender K.D., Albers D.S., Iadarola M.J., Landwehrmeyer G.B., Standaert D.G. Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons. J Comp Neurol. 415:1999;204-217
112. Küppenbender K.D., Standaert D.G., Feuerstein T.J., Penney J.B. Jr., Young A.B., Landwehrmeyer G.B. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol. 419:2000;407-421
113. Kuryatov A., Laube B., Betz H., Kuhse J. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron. 12:1994;1291-1300
114. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med. 339:1998;1044-1053
115. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med. 339:1998;1130-1143
116. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 21:1997;393-400
117. Langston J.W. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol. 44:1998;S45-S52
118. Lau L.F., Huganir R.L. Differential tyrosine phosphorylation of N-methyl-D-aspartate receptor subunits. J Biol Chem. 270:1995;20036-20041
119. Laube B., Hirai H., Sturgess M., Betz H., Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron. 18:1997;493-503
120. Laube B., Kuhse J., Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci. 18:1998;2954-2961
121. Lee F.J., Xue S., Pei L., Vukusic B., Chery N., Wang Y., Wang Y.T., Niznik H.B., Yu X.M., Liu F. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell. 111:2002;219-230
122. Leonard A.S., Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J Biol Chem. 272:1997;12107-12115
123. Levine M.S., Li Z., Cepeda C., Cromwell H.C., Altemus K.L. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse. 24:1996;65-78
124. Levine M.S., Altemus K.L., Cepeda C., Cromwell H.C., Crawford C., Ariano M.A., Drago J., Sibley D.R., Westphal H. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J Neurosci. 16:1996;5870-5882
125. Levy R., Hazerati L.-N., Herrero M.-T., Vila M., Hassan O.-K., Mouroux M., Ruberg M., Aseni H., Agid Y., Féger J., Obeso J.A., Parent A., Hirsch E.C. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience. 76:1997;335-343
126. Liao G.Y., Wagner D.A., Hsu M.H., Leonard J.P. Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current. Mol Pharmacol. 59:2001;960-964
127. Lieberman D.N., Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature. 369:1994;235-239
128. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A.-L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 339:1998;1105-1111
129. Lin J.W., Wyszynski M., Madhavan R., Sealock R., Kim J.U., Sheng M. Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. J Neurosci. 18:1998;2017-2027
130. Lindskog M., Svenningsson P., Fredholm B.B., Greengard P., Fisone G. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience. 88:1999;1005-1008
131. Loftis J.M., Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther. 97:2003;55-85
132. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 15:2000;873-878
133. Lynch D.R., Anegawa N.J., Verdoorn T., Pritchett D.B. N-Methyl-D-aspartate receptors - different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol Pharmacol. 45:1994;540-545
134. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205
135. Marino M.J., Valenti O., Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging. 20:2003;377-397
136. Marti M., Paganini F., Stocchi S., Mela F., Beani L., Bianchi C., Morari M. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J Neurochem. 84:2003;792-802
137. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. NeuroReport. 7:1995;125-128
138. Meoni P., Bunnemann B.H., Kingsbury A.E., Trist D.G., Bowery N.G. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson's disease patients. Neuropharmacology. 38:1999;625-633
139. Merello M., Nouzeilles M.I., Cammarota A., Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol. 22:1999;273-276
140. Mereu G., Costa E., Armstrong D.A., Vicini S. Glutamate receptor subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J Neurosci. 11:1991;1359-1366
141. Mink J.W. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 50:1996;381-425
142. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., Crossman A.R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neuroscience. 32:1989;213-226
143. Mitchell I.J., Hughes N., Carroll C.B., Brotchie J.M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav Pharmacol. 6:1995;492-507
144. Miwa H., Nishi K., Fuwa T., Mizuno Y. Postural effects of unilateral blockade of glutamatergic neurotransmission in the subthalamic nucleus on haloperidol-induced akinesia in rats. Neurosci Lett. 252:1998;167-170
145. Monaghan D., Bridges R., Cotman C. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol. 29:1989;365-402
146. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:1994;529-540
147. Moon I.S., Apperson M.L., Kennedy M.B. The major tyrosine-phosphorylated protein in the postsynaptic density fraction is N-methyl-D-aspartate receptor subunit 2B. Proc Natl Acad Sci USA. 91:1994;3954-3958
148. Morari M., O'Connor W.T., Ungerstedt U., Fuxe K. N-Methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study. J Neurochem. 60:1993;1884-1893
149. Morelli M., Fenu S., Pinna A., Di Chiara G. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther. 260:1992;402-408
150. Moresco R.M., Volonte M.A., Messa C., Gobbo C., Galli L., Carpinelli A., Rizzo G., Panzacchi A., Franceschi M., Fazio F. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET-[(11)C]raclopride study. J Neural Transm. 109:2002;1265-1274
151. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 354:1991;31-37
152. Mouradian M.M., Heuser I.J.E., Baronti F., Chase T.N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 27:1990;18-23
153. Naisbitt S., Kim E., Weinberg R.J., Rao A., Yang F.-C., Craig A.M., Sheng M. Characterization of guanylate kinase-associated protein, a postsynaptic density protein at excitatory synapses that interacts directly with postsynaptic density-95/synapse-associated protein 90. J Neurosci. 17:1997;5687-5696
154. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603
155. Nakanishi H., Kita H., Kitai S. An N-methyl-D-aspartate receptor mediated excitatory postsynaptic potential evoked in subthalamic neurons in an in vitro slice preparation of the rat. Neurosci Lett. 95:1988;130-136
156. Nambu A., Tokuno H., Hamada I., Kita H., Imanishi M., Akazawa T., Ikeuchi Y., Hasegawa N. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol. 84:2000;289-300
157. Nash J.E., Brotchie J.M. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord. 17:2002;455-466
158. Nash J.E., Hill M.P., Brotchie J.M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol. 155:1999;42-48
159. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol. 165:2000;136-142
160. Niethammer M., Kim E., Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci. 16:1996;2157-2163
161. Nishi A., Snyder G.L., Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 17:1997;8147-8155
162. Nishi M., Hinds H., Lu H.P., Kawata M., Hayashi Y. Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci. 21:2001;RC185
163. Obeso J.A., Rodriguez M.C., DeLong M.R. Basal ganglia pathophysiology. A critical review. Adv Neurol. 74:1997;3-18
164. O'Brien R.J., Lau L.-F., Huganir R.L. Molecular mechanisms of glutamate receptor clustering at excitatory synapses. Curr Opin Neurobiol. 8:1998;364-369
165. O'Dell S.J., Marshall J.F. Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury. NeuroReport. 7:1996;2457-2461
166. Oh J.D., Russell D., Vaughan C.L., Chase T.N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813:1998;150-159
167. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821:1999;433-442
168. Omkumar R.V., Kiely M.J., Rosenstein A.J., Min K.T., Kennedy M.B. Identification of a phosphorylation site for calcium/calmodulindependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 271:1996;31670-31678
169. Onn S.P., Grace A.A. Alterations in electrophysiological activity and dye coupling of striatal spiny and aspiny neurons in dopamine-denervated rat striatum recorded in vivo. Synapse. 33:1999;1-15
170. Overton P., Clark D. Iontophoretically administered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse. 10:1992;131-140
171. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol. 39:1996;574-578
172. Papa S.M., Engber T.M., Boldry R.C., Chase T.N. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol. 232:1993;247-253
173. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18
174. Parent A., Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov Disord. 13:1998;199-202
175. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. 1. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev. 20:1995;91-127
176. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. 2. The place of the subthalamic nucleus and external pallidum in basal ganglia ciruitry. Brain Res Rev. 20:1995;128-154
177. Parkinson Study Group A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology. 54:2000;1583-1588
178. Parkinson Study Group Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol. 58:2001;1660-1668
179. Paul S., Snyder G.L., Yokakura H., Picciotto M.R., Nairn A.C., Lombroso P.J. The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J Neurosci. 20:2000;5630-5638
180. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., Morgenstern R., Kupsch A. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol. 185:2004;272-280
181. Penney J.B., Young A.B. Striatal inhomogeneities and basal ganglia function. Mov Disord. 1:1986;3-15
182. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 6:2003;501-506
183. Pisani A., Bonsi P., Centonze D., Gubellini P., Bernardi G., Calabresi P. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology. 45:2003;45-56
184. Polymeropoulos M.H., Levedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Pappetropoulso T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di lorio G., Golbe L.I., Nussbaum R.L. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047
185. Porter R.H.P., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci. 14:1994;7192-7200
186. Premkumar L.S., Auerbach A. Stoichiometry of recombinant N-methyl-D-aspartate receptor channels inferred from single-channel current patterns. J Gen Physiol. 110:1997;485-502
187. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 13:1998;35-38
188. Raman I.M., Tong G., Jahr C.E. Beta-adrenergic regulation of synaptic NMDA receptors by cAMP-dependent protein kinase. Neuron. 16:1996;415-421
189. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol. 47:2000;S179-S188
190. Ravenscroft P., Brotchie J. NMDA receptors in the basal ganglia. J Anat. 196:2000;577-585
191. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 60:2003;1234-1240
192. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 44:1998;S175-S188
193. Rostas J.A., Brent V.A., Voss K., Errington M.L., Bliss T.V., Gurd J.W. Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. Proc Natl Acad Sci USA. 93:1996;10452-10456
194. Ruzicka B.B., Jhamandas K. Met-enkephalin release from slices of the rat striatum and globus pallidus: stimulation by excitatory amino acids. J Pharmacol Exp Ther. 257:1991;1025-1033
195. Saka E., Iadarola M., Fitzgerald D.J., Graybiel A.M. Local circuit neurons in the striatum regulate neural and behavioral responses to dopaminergic stimulation. Proc Natl Acad Sci USA. 99:2002;9004-9009. (Epub 2002 Jun 9011)
196. Samuel D., Errami M., Nieoullon A. Localization of N-methyl-D-aspartate receptors in the rat striatum: effects of specific lesions on the [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid binding. J Neurochem. 54:1990;1926-1933
197. Sans N., Prybylowski K., Petralia R.S., Chang K., Wang Y.X., Racca C., Vicini S., Wenthold R.J. NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat Cell Biol. 5:2003;520-530
198. Schell M.J., Bracy R.O., Molliver M.E., Synder S.H. D-Serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci. 17:1997;1604-1615
199. Schultz W. Multiple reward signals in the brain. Nat Rev. 1:2000;199-207
200. Sethi K.D. Clinical aspects of Parkinson disease. Curr Opin Neurol. 15:2002;457-460
201. Smith Y., Bennett B.D., Bolam J.P., Parent A., Sadikot A.F. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J Comp Neurol. 344:1994;1-19
202. Smith Y., Charara A., Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol. 364:1996;231-253
203. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387
204. Smith Y., Charara A., Paquet M., Kieval J.Z., Pare J.F., Hanson J.E., Hubert G.W., Kuwajima M., Levey A.I. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia. J Chem Neuroanat. 22:2001;13-42
205. Snyder G.L., Fienberg A.A., Huganir R.L., Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phophatase-1 pathway regulated dephosphorylation of the NMDA receptor. J Neurosci. 18:1998;10297-10303
206. 5-enkephalin biosynthesis in neurons of the rat striatum. J Pharmacol Exp Ther. 262:1992;823-833
207. Srivastava S., Osten P., Vilim F.S., Khatri L., Inman G., States B., Daly C., DeSouza S., Abagyan R., Valtschanoff J.G., Weinberg R.J., Ziff E.B. Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP. Neuron. 21:1999;581-591
208. Standaert D.G., Stern M.B. Update on the management of Parkinson's disease. Med Clin North Am. 77:1993;169-183
209. Standaert D.G., Young A.B. Treatment of central nervous system degenerative disorders. Hardman J.G., Limbird L.E., Goodman Gilman A. Goodman and Gilman's Pharmacological Basis of Therapeutics. 10th Ed. 2001;549-568 McGraw-Hill
210. Standaert D.G., Testa C.M., Penney J.B., Young A.B. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol. 343:1994;1-16
211. Standaert D.G., Landwehrmeyer G.B., Kerner J.A., Penney J.B., Young A.B. Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex, and hippocampus. Mol Brain Res. 42:1996;89-102
212. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., Penney J.B. Jr. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Mol Brain Res. 64:1999;11-23
213. Starr M.S., Starr B.S. Facilitation of dopamine-D1 receptor-dependent but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur J Pharmacol. 250:1993;239-246
214. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101, 606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp Neurol. 163:2000;239-243
215. Stern E.A., Jaeger D., Wilson C.J. Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo. Nature. 394:1998;475-478
216. Stoof J.C., Booij J., Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg. 94:1992;S4-S6. (Suppl.)
217. Sucher N.J., Awobuluyi M., Choi Y.-B., Lipton S.A. NMDA receptors: from genes to channels. Trends Pharmacol Sci. 17:1996;348-355
218. Sugihara H., Moriyoshi K., Ishii T., Masu M., Nakanishi S. Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem Biophys Res Commun. 185:1992;826-832
219. Sullivan J.M., Traynelis S.F., Chen H.S., Escobar W., Heinemann S.F., Lipton S.A. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. Neuron. 13:1994;929-936
220. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature. 401:1999;63-69
221. Tanner C.M. Epidemiology of Parkinson's disease. Neurol Clin. 10:1992;317-329
222. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., Langston J.W. Parkinson disease in twins: an etiologic study. J Am Med Assoc. 281:1999;341-346
223. Thanos P.K., Jhamandas K., Beninger R.J. N-Methyl-D-aspartate unilaterally injected into the dorsal striatum of rats produces contralateral circling: antagonism by 2-amino-7-phosphonoheptanoic acid and cis-flupenthixol. Brain Res. 589:1992;55-61
224. Tingley W.G., Ehlers M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem. 272:1997;5157-5166
225. Traynelis S.F., Hartley M., Heinemann S.F. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 268:1995;873-876
226. Traynelis S.F., Burgess M.F., Zheng F., Lyuboslavsky P., Powers J.L. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci. 18:1998;6163-6175
227. Uitti R., Rajput A., Ahlskog J., Offord K., Schroeder D., Ho M., Prasad M., Rajput A., Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology. 46:1996;1551-1556
228. Ulas J., Cotman C.W. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. NeuroReport. 7:1996;1789-1793
229. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J Neurosci. 14:1994;6317-6324
230. Verhagen Metman L., Del Dotto P., Natte R., van den Munckhof P., Chase T.N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51:1998;203-206
231. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326
232. Verhagen Metman L., Blanchet P.J., van den Munckhof P., Del Dotto P., Natte R., Chase T.N. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord. 13:1998;414-417
233. Vyklicky L. Jr., Vlachova V., Krusek J. The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J Physiol. 430:1990;497-517
234. Wang L.Y., Orser B.A., Brautigan D.L., MacDonald J.F. Regulation of NMDA receptors in cultured hippocampal neurons by protein phosphatases 1 and 2A. Nature. 369:1994;230-232
235. Wechsler A., Teichberg V.I. Brain spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin. Embo J. 17:1998;3931-3939
236. Weihmuller F.B., Ulas J., Nguyen L., Cotman C.W., Marshall J.F. Elevated NMDA receptors in parkinsonian striatum. NeuroReport. 3:1992;977-980
237. Weiss S.W., Albers D.S., Iadarola M.J., Dawson T.M., Dawson V.L., Standaert D.G. NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical, and hippocampal nitric oxide synthase neurons. J Neurosci. 18:1998;1725-1734
238. Wenthold R.J., Prybylowski K., Standley S., Sans N., Petralia R.S. Trafficking of NMDA receptors. Annu Rev Pharmacol Toxicol. 43:2003;335-358
239. Wenzel A., Villa M., Mohler H., Benke D. Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. J Neurochem. 66:1996;1240-1248
240. Westphal R.S., Tavalin S.J., Lin J.W., Alto N.M., Fraser I.D.C., Langeberg L.K., Sheng M., Scott J.D. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science. 285:1999;93-96
241. Whittemore E.R., Ilyin V.I., Woodward R.M. Electrophysiological characterization of CI-1041 on cloned and native NMDA receptors. 2000 Abstract Viewer/Itinerary Planner. 2000;Society for Neuroscience, Washington, DC. Online. Program No. 527.3
242. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 44:1993;851-859
243. Williams K. Modulation of the N-methyl-D-aspartate receptor by polyamines: molecular pharmacology and mechanisms of action. Biochem Soc Trans. 22:1994;884-887
244. Williams K. Pharmacological properties of recombinant N-methyl-D-aspartate receptors containing the epsilon-4 (NR2D) subunit. Neurosci Lett. 184:1995;181-184
245. Wolosker H., Sheth K.N., Takahashi M., Mothet J.P., Brady R.O. Jr., Ferris C.D., Snyder S.H. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA. 96:1999;721-725
246. Wüllner U., Testa C.M., Catania M.V., Young A.B., Penney J.B. Jr. Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645:1994;98-102
247. Wüllner U., Standaert D.G., Testa C.M., Landwehrmeyer G.B., Catania M.V., Penney J.B. Jr., Young A.B. Glutamate receptor expression in rat striatum: effect of deafferentation. Brain Res. 647:1994;209-219
248. Wyszynski M., Lin J., Rao A., Nigh E., Beggs A.H., Craing A.M., Sheng M. Competitive binding of α-actinin and calmodulin to the NMDA receptor. Nature. 385:1997;439-442
249. Wyszynski M., Kharazia V., Shanghvi R., Rao A., Beggs A.H., Crain A.M., Weinberf R., Sheng M. Differential regional expression and ultrastructural localization of alpha-actinin-2, a putative NMDA receptor anchoring protein, in rat brain. J Neurosci. 18:1998;1383-1392
250. Wyszynski M., Kim E., Yang F.C., Sheng M. Biochemical and immunocytochemical characterization of GRIP, a putative AMPA receptor anchoring protein, in rat brain. Neuropharmacology. 37:1999;1335-1344
251. Wyszynski M., Valtschanoff J.G., Naisbitt S., Dunah A.W., Kim E., Standaert D.G., Weinberg R., Sheng M. Association of AMPA receptors with a subset of glutamate receptor-interacting proteins in vivo. J Neurosci. 19:1999;6528-6537
252. Xia J., Zhang X., Staudinger J., Huganir R.L. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron. 22:1999;179-187
253. Xiao B., Tu J.C., Petralia R.S., Yuan J.P., Doan A., Breder C.D., Ruggiero A., Lanahan A.A., Wenthold R.J., Worley P.F. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron. 21:1998;707-716
254. Xiong Z.G., Pelkey K.A., Lu W.Y., Lu Y.M., Roder J.C., MacDonald J.F., Salter M.W. Src potentiation of NMDA receptors in hippocampal and spinal neurons is not mediated by reducing zinc inhibition. J Neurosci. 19:1999;RC37
255. Young A.M.J., Bradford H.F. N-Methyl-D-aspartate releases excitatory amino acids in rat corpus striatum in vivo. J Neurochem. 56:1991;1677-1683
256. Young A.M.J., Bradford H.F. N-Methyl-D-aspartate releases γ-aminobutyric acid from rat striatum in vivo: a microdialysis study using a novel preloading method. J Neurochem. 60:1993;487-492
257. Zigmond M.J., Castro S.L., Keefe K.A., Abercrombie E.D., Sved A.F. Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids. 14:1998;57-62
258. Zukin R.S., Bennett M.V.L. Alternatively spliced isoforms of the NMDAR1 receptor subunit. Trends Neurosci. 18:1995;306-313